Hung Out As Axovant Rebuilds Its Pipeline, Expands Focus Beyond Dementia

CEO Hung resigns after less than a year; he and several others leave behind a dementia-focused specialty pharma that will return to its entrepreneurial roots to build a broader neuroscience pipeline. Parent company Roivant turns to a less conventional choice, Parvan Cheruvu, to take the helm.